FTLD-ALS spectrum
Conditions
Interventions
Sponsors
National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology
Center for Brain and Mind Research Promotion, Nagoya University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) FTLD-ALS spectrum patients 1. 20 years of age or older at the time of obtaining consent 2. Subjects who can be accompanied by a legal guardian on the day of study participation 3. Subjects met with clinical diagnostic criteria of ALS or FTLD 2) Healthy volunteers 1. 20 years of age or older at the time of obtaining consent 2. Subjects with ability to make informed consent
Exclusion criteria
Exclusion criteria: 1) FTLD-ALS spectrum patients 1. Subjects with organic brain complications/disorders 2. Subjects with substance-related disorders 3. Subjects with severe physical complications/disorders or a history of such conditions 4. Subjects with claustrophobia 5. Pregnant, possibly pregnant or lactating women 6. From the standpoint of radiation exposure from a nuclear medicine scan, subjects who have participated in other nuclear medicine scans as healthy volunteers in the 6 months prior to the start of this study (at National Institutes for Quantum and Radiological Science and Technology) 7. Subjects with metallic medical device in the body (at Nagoya university) 8. Subjects with tattoo (at Nagoya university) 9. Subjects who are considered to be inappropriate for participation by doctors with responsibilities in this study 2) Healthy volunteers 1. Subjects with organic brain complications/disorders 2. Subjects with substance-related disorders 3. Subjects with severe physical complications/disorders or a history of such conditions 4. Subjects with metallic medical device in the body 5. Subjects with tattoo 6. Subjects with claustrophobia 7. Pregnant, possibly pregnant or lactating women 8. From the standpoint of radiation exposure from a nuclear medicine scan, subjects who have participated in other nuclear medicine scans as healthy volunteers in the 6 months prior to the start of this study (at National Institutes for Quantum and Radiological Science and Technology) 9. Subjects who are considered to be inappropriate for participation by doctors with responsibilities in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The associations between neurotransmitter systems evaluated by PET with (E)-[11C]ABP688 and MRI/MRS, and clinical symptoms. | — |
Secondary
| Measure | Time frame |
|---|---|
| The associations between neurotransmitter systems evaluated by PET with (E)-[11C]ABP688 and MRI/MRS, and abnormally aggregated protein measured by PET with [18F]PM-PBB3 and [11C]PiB. | — |
Countries
Japan
Contacts
Public ContactKazuko Suzuki
National Institutes for Quantum and Radiological Science and Technology Clinical Research Support Section, National Institute of Radiological Sciences
Outcome results
None listed